[1]张秀娟,黄丽娟.mTOR、PTEN、Ki-67蛋白表达水平变化与结肠癌病理学特征的相关性分析[J].医学信息,2022,35(19):54-56.[doi:10.3969/j.issn.1006-1959.2022.19.014]
　ZHANG Xiu-juan,HUANG Li-juan.Correlation of mTOR, PTEN and Ki-67 Protein Expression with Pathological Features of Colon Cancer[J].Journal of Medical Information,2022,35(19):54-56.[doi:10.3969/j.issn.1006-1959.2022.19.014]
点击复制

mTOR、PTEN、Ki-67蛋白表达水平变化与结肠癌病理学特征的相关性分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年19期
页码:
54-56
栏目:
论著
出版日期:
2022-10-01

文章信息/Info

Title:
Correlation of mTOR, PTEN and Ki-67 Protein Expression with Pathological Features of Colon Cancer
文章编号:
1006-1959（2022）19-0054-03
作者:
张秀娟; 黄丽娟
（新疆生产建设兵团第二师库尔勒医院病理科，新疆 库尔勒 841000）
Author(s):
ZHANG Xiu-juan; HUANG Li-juan
(Department of Pathology,Korla Hospital of the Second Division of Xinjiang Production and Construction Corps,Korla 841000,Xinjiang,China)
关键词:
哺乳动物雷帕霉素靶蛋白; 张力蛋白同源蛋白; Ki-67蛋白; 结肠癌
Keywords:
Mammalian target of rapamycin; Phosphatase and tensin homologue deleted on chromosomen; Ki-67 protein; Colon cancer
分类号:
R735.3+5
DOI:
10.3969/j.issn.1006-1959.2022.19.014
文献标志码:
A
摘要:
目的 探讨哺乳动物雷帕霉素靶蛋白（mTOR）、张力蛋白同源蛋白（PTEN）、Ki-67蛋白表达与结肠癌病理学特征的相关性。方法 收集2013年3月-2016年6月我院病理科收集的90例结肠癌组织标本（结肠癌组）、45例正常结肠组织（对照组），采用免疫组化染色检测两组标本中mTOR、PTEN、Ki-67蛋白的表达情况，并分析三种蛋白不同的淋巴结转移、TNM分期、肿瘤分化程度结肠癌组织中的表达差异。结果 结肠癌组mTOR蛋白、Ki-67蛋白阳性表达率分别为71.11%、74.44%，高于对照组的13.33%、20.00%，差异有统计学意义（P＜0.05）；结肠癌组PTEN蛋白阳性表达率为23.33%，低于对照组的93.33%，差异有统计学意义（P＜0.05）；不同TNM分期、是否发生淋巴结转移、不同肿瘤分化的结肠癌组织中mTOR蛋白、PTEN蛋白、Ki-67蛋白阳性表达率分别比较，差异有统计学意义（P＜0.05）。结论 结肠癌组织中mTOR蛋白、Ki-67蛋白高表达，PTEN蛋白低表达，并且与肿瘤的发生发展关系密切。
Abstract:
Objective To investigate the relationship between the expression of mammalian target of rapamycin (mTOR), phosphatase and tensin homologue deleted on chromosome (PTEN), Ki-67 protein and the pathological features of colon cancer.Methods From March 2013 to June 2016,90 cases of colon cancer tissues ( colon cancer group ) and 45 cases of normal colon tissues ( control group ) were collected from the Department of Pathology of our hospital. The expression of mTOR, PTEN and Ki-67 protein in the two groups was detected by immunohistochemical staining, and the expression differences of the three proteins in different lymph node metastasis, TNM stage and tumor differentiation were analyzed.Results The positive expression rates of mTOR protein and Ki-67 protein in colon cancer group were 71.11% and 74.44% respectively, which were higher than 13.33% and 20.00% in control group, and the differences were statistically significant (P<0.05). The positive expression rate of PTEN protein in colon cancer group was 23.33%, which was lower than 93.33% in control group, and the difference was statistically significant (P<0.05). The positive expression rates of mTOR protein, PTEN protein and Ki-67 protein in colon cancer tissues with different TNM stages, lymph node metastasis and tumor differentiation were significantly different (P<0.05).Conclusion mTOR protein and Ki-67 protein are highly expressed in colon cancer tissues, and PTEN protein is lowly expressed, which is closely related to the occurrence and development of tumors..

参考文献/References:

[1]Landi P,Dorado E,Paz LA.Colon cancer with abdominal wall infiltration and clinical factors of poor prognosis[J].Medicina (B Aires),2016,76(6):403-407.[2]黄许森,王宇,黄海舸,等.PTEN基因在结肠癌患者不同组织中表达的意义[J].结直肠肛门外科,2016,22(2):113-115.[3]郭星,王前,李晓宁,等.STMN1及PTEN在结肠癌组织中的表达及意义[J].中国现代普通外科进展,2016,19(6):460-464.[4]涂志强,杨海燕,杨敏.术前血清癌胚抗原水平与结肠癌临床病理特征及其预后关系的分析[J].实用癌症杂志,2018,33(2):301-302.[5]葛洋,刘宝林.艾迪注射液联合雷替曲塞治疗晚期结肠癌的临床研究[J].现代药物与临床,2017,32(11):2203-2206.[6]王宇,姜修博,韩豆,等.竹节香附素A对人结肠癌细胞HCT-116增殖、凋亡、迁移及侵袭活性的影响[J].中药新药与临床药理,2018,29(2):123-130.[7]Fisher TS,Hooper AT,Lucas J,et al.A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice[J].Cancer Immunol Immunother,2018,67(2):247-259.[8]杨晓萍.单颖关于错配修复基因蛋白表达的检测对结肠癌患者预后价值的临床意义研究[J].标记免疫分析与临床,2018,25(3):339-341.[9]彭炜,周明.喉癌组织中Six1、MTDH、TKTL1表达量与血清肿瘤标志物含量、细胞增殖活力的相关性[J].海南医学院学报,2017,23(15):2040-2043.[10]Dasen B,Vlajnic T,Mengus C,et al.T-cadherin in prostate cancer: relationship with cancer progression, differentiation and drug resistance[J].J Pathol Clin Res,2017,3(1):44-57.[11]许星宇,陈博,熊茂明.p-mTOR在胃癌组织中的表达与临床病理及预后的关系[J].中华普通外科杂志,2016,31(2):145-148.[12]马志恒,蒋海存,陈建新,等.mTOR信号通路与胃癌的相关性研究[J].国际消化病杂志,2016,36(4):256-258.[13]张春,李清漪,董海影,等.PI3K/AKT/mTOR信号通路在诱导胶质瘤细胞凋亡中的作用[J].中国新药杂志,2016,25(16):1909-1912.[14]刘田田,毕经旺.PI3K/Akt/mTOR信号通路与结直肠恶性肿瘤[J].实用医药杂志,2016,33(4):367-370,374.[15]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[16]Fu X,Huang Y,Fan X,et al.Demographic trends and KRAS/BRAF mutations in colorectal cancer patients of South China: a single-site report[J].Int J Cancer,2019,144(9):2109-2117.[17]王茜,时延龙,毕经旺.p-mTOR与HIF-1α在结直肠癌组织中的表达及其临床意义[J].中国肿瘤生物治疗杂志,2016,22(6):779-784.[18]张少华,毕经旺.结直肠癌组织中S6K1及4EBP1蛋白的表达及其与临床病理特征的关系[J].中国肿瘤生物治疗杂志,2017,22(6):747-753.[19]郝东明,张丽.姜黄素联合伊立替康对结肠癌SW620细胞的体外抑制作用[J].现代药物与临床,2016,31(6):731-732.[20]孙红兰,刘慧峰,姜国丹.p-MTOR在结肠癌中的表达及与患者病理学特征的关系[J].癌症进展,2018,16(1):70-72.

更新日期/Last Update: 1900-01-01